Abstract: The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of treating and preventing vaginal infections. Compositions useful in supporting healthy microflora, disclosed herein, generally comprise a therapeutic amount of a first saccharide and a therapeutic amount of a second saccharide or an organic acid. The saccharides may be, for example, a pentose, a disaccharide, a cyclodextrin, a pectic substance or a non-digestible polysaccharide. The organic acid may be, for example, malic acid.

Abstract: An orally administrable micellar composition is provided. The composition comprises a pharmaceutical agent encapsulated in micelles formed by at least one micelle-forming compound in a pharmaceutically acceptable aqueous solvent comprising an alkali metal salicylate and a pharmaceutically acceptable edetate combined with at least one physiologically acceptable film forming agent.

Abstract: The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human, a method for using creatinine to improve the bioavailability of creatine, and a metn.

Abstract: The present invention relates to hot flash-suppressing agents and menopausal disorder-improving agents and a food and drink and a pharmaceutical preparation for suppressing hot flash, containing ?-lactalbumin as an active ingredient.

Abstract: Composition for treatment and management of addiction and method of preparation thereof are disclosed herein. The disclosed herbal composition includes herb and mineral which facilitate in treating addiction. It may be used to treat addiction such as alcohol addiction, tobacco addiction, excessive smoking, drugs abuse etc. Further, the disclosed composition may also be instrumental in treating complications associated with addiction and withdrawal symptoms.

Abstract: The invention relates to an oral tablet for delivery of active ingredients to the throat comprising a population of particles and an active ingredient to be delivered to the throat, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the throat as part of the saliva generated upon mastication of the tablet.

Abstract: A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.

Abstract: The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders.

Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.

Abstract: A film forming composition comprises a film forming component and a solvent, wherein the film forming component comprises 0-50 wt % of a first water soluble polymer, 0.3-40 wt % of a second water soluble polymer, 0-15 wt % of plasticizer and 50-70 wt % of active ingredient. The first and second water soluble polymers have a Tg of ?52° C. to 216° C., and difference of Tg values of the first and second water soluble polymer is 62-268° C. The film formed by the film forming composition capable to load high content of active ingredient and lead to fast absorption of active ingredient is provided.

Abstract: A formulated oral prebiotic edible composition useful for promoting a desired oral microbiota to treat a respiratory allergic condition and/or an oral and/or sinus infection condition in a subject in need of such treatment, the oral prebiotic including comprising L-arginine, the L-arginine including free individual molecules of L-arginine, the free individual molecules of L-arginine L present at a concentration of greater than about 0.1 wt %; a carrier, and a sugar comprising at least one of a monosaccharide and disaccharide; the composition in a configuration suitable to be maintained including being substantially dissolved within the oral cavity for over a period of at least about 1 minute to about an hour, the composition in an effective amount to thereby selectively promote an increased concentration of oral microbiota to thereby treat the respiratory and/or oral and/or sinus related allergy condition, the selected oral microbiota including Veillonella and Streptococcus.

Abstract: Methods for managing the body mass index, the body fat percentage and/or the distribution of fat storage sites of humans are provided, and more particularly the use of food compositions for managing the body mass index, the body fat percentage and/or the distribution of fat storage sites by administering to a human in need of managing body mass index, body fat percentage and/or distribution of fat storage sites an effective amount of a food formulation comprised of an esterified pectin having a degree of esterification (DE) of less than 65%.

Abstract: Provided are food products having structures, textures, and other properties similar to those of animal meat, and that comprise substantial amounts of cell wall material. Also provided are methods and processes for producing such food products.

Abstract: The present invention primarily relates to the use of Homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion-stimulating effect of N-Acetyl-4-aminophenol (Paracetamol).

Abstract: Compositions comprising polysaccharides and oligosaccharides are provided. Methods for the formation of the compositions, including the enzymatic production of the oligosaccharides, and the uses of the compositions in foodstuffs, cosmetics, and nutraceuticals are also provided.

Abstract: Methods of preparing a delivery system are described. Each method uses a first and second printing materials. The second printing material contains an active material such as a fragrance, flavor, malodor counteracting agent, and mixture thereof.

Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B6 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B6 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

Abstract: A synergistic herbal stimulant composition comprises a mixture, in powdered or extract form, of two or more herbal stimulant ingredients and at least one catalytic herbal ingredient, which effects a synergy between the herbal stimulant ingredients. The herbal stimulant ingredients are preferably selected from the group consisting of Horny Goat Weed (Epimedium Sagittatum), Rhodiola Root (Rhodiola Rosea), Elueuthero Root (Eleutherococcus), Nettle Leaf (Urticaria Dioica), Ashwagandha Root (Withania Somnifera), Maca Root (Lepidium Meyenii), Moringa Root (Moringa Oleifera), and Cowitch (Macuna Pruriens). The catalytic herbal ingredient is preferably Moses-in-a-basket (Tradescantia Spathacea).

Abstract: This invention provides a method of colonic cleansing.

Abstract: The invention provides a smokeless tobacco product comprising a tobacco extract. In some embodiments, the smokeless tobacco product is translucent. The invention further provides methods for making and using the smokeless tobacco product. In certain embodiments, the smokeless tobacco product comprises isomalt, maltitol syrup, and a translucent tobacco extract prepared by ultrafiltration.

Abstract: The present disclosure relates to the use of lipophilic mercaptans for the treatment of pain sensitization. The lipophilic mercaptans disclosed can be used to decrease the formation of protein-aldehyde adducts within nociceptive nerves, thereby reducing sensitization to pain.

Abstract: Generating an optimised formulation for a foodstuff, comprises receiving at a processor physicochemical data pertaining to one or more plant extracts and operating the processor to calculate a time, Tmax, representing a time to reach a maximum concentration in plasma of at least one metabolite of the one or more plant extracts by applying the received physicochemical data to a mathematical model stored in memory. The processor is then operated to identify ones of the metabolites for which the calculated Tmax substantially corresponds with a target absorption time for the foodstuff; and to generate an optimised formulation for the foodstuff comprising the one or more plant extracts containing the identified metabolites. The physicochemical data include one or more of molecular mass (M), liphophilicity (log P) and Polar Surface Area (PSA).

Abstract: The present invention relates to an agrochemical combination of (i) linolenic acid, a linolenic acid derivative, a linolenic acid breakdown component, or an ester thereof; and (ii) inositol, an inositol derivative or an inositol breakdown component. The invention also relates to agrochemical compositions comprising the same and the use such a combination for improving plant physiology.

Abstract: Methods are disclosed for the enzymatic preparation of galactooligosaccharide (GOS) from lactose using two different microbial lactase enzymes to maximize the extent of transgalactosylation during the digestion of lactose. Methods are also disclosed for avoiding the turbidity of a solution comprising GOS and lactose as it is adjusted for incubation with a yeast neutral lactase.

Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Abstract: This disclosure relates to a supplement, particularly a supplement for menopause.

Abstract: The present disclosure provides for methods and compositions for the treatment and prevention of antibiotic-resistant infections or pathogen colonization in critically ill patients in the intensive care unit (ICU) or in other populations at high risk for such infections.

Abstract: A method of increasing muscle mass and strength in mammals by orally administering a therapeutically effective amount of phosphatidic acid. The phosphatidic acid is preferably administered as a plurality of doses per day with at least one dose being administered during the anabolic window following exercise. Preferably, the method further includes the cotemporaneous administration of a therapeutically effective amount of creatine, optionally as phosphatidylcreatine. In addition or in the alternative, the method further includes the cotemporaneous administration of a therapeutically effective amount of leucine, optionally as phosphatidylleucine.

Abstract: A dietary supplement including monacolin K, phytosterols, policosanols, resveratrol, trimethylglycine and coenzyme Q10 is provided.

Abstract: Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from medium chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.

Abstract: An encapsulated reactant(s) having at least one encapsulant and at least one reactant. An outermost encapsulant is substantially non-reacting, impermeable and non-dissolving with water. The reactant(s) contribute to at least one reaction with contaminants in environmental media rendering the environmental media less harmful. Processes for using the encapsulated reactant in environmental media is also hereby claimed.

Abstract: Embodiments of the present invention are directed to methods, apparatus and articles of manufacture that feature omega-3 fatty acids co-processed with flavonoid and lipophilic antioxidants for improved stability.

Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.

Abstract: This document provides dietary supplement compositions as well as methods for using dietary supplement compositions to control glucose levels. For example, a dietary supplement composition including chromium (e.g., Chromium Oligofructose Complex), a sweet potato extract, and one or more of a mulberry extract, a green tea extract, a cinnamon extract, or a ginseng extract (e.g., Korean Red Ginseng extract) are provided.

Abstract: An iron-based composition is described. The composition can be used in conditions of total or relative iron deficiency. In particular, a solid composition is described, preferably in the form of powder or granules, for use in the treatment of disorders or diseases related to or derived from an iron deficiency. The composition is suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. Finally, a process for preparing the solid composition is also described.

Abstract: Method of reducing the mTOR pathway stimulating activity of amino acid containing nutritional materials. This method comprises treating an enzymatically hydrolysed protein material such as casein, whey, or soy protein with at least one enzyme capable of converting mTOR pathway stimulating amino acids and amino acid residues, such as leucine or methionine, into alternate chemical entities that do not stimulate or stimulate to a significantly lesser degree the mTOR pathway, while preserving the non-mTOR stimulating amino acids. These one or more alternate chemical entities should ideally be suitable for consumption, or alternatively be capable of being removed from the treated material through low cost extraction or conversion techniques. The material may then be sold as is, or alternatively packaged with low glycemic carbohydrates, healthy lipids, vitamins, and flavors and sold as a variety of different food products intended for an artificial diet intended to mimic the effects of caloric restriction.

Abstract: Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninhotis, and Xanthomonas arboricola pathovar pruni, a producer of pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described, and they may be applied to the gingival mucosa and/or alveolar mucosa on the buccal (1) or lingual/buccal (2) surfaces with extensions and anatomical contours for crowns of the upper and lower dental arches.

Abstract: The present disclosure discloses a nutritional composition for nourishing heart. The nutritional composition includes: 58-83 parts by weight of rice, 7-25 parts by weight of red beans, 5-16 parts by weight of lotus seeds, 2-7 parts by weight of lilium brownii, and 0.4-1.6 parts by weight of longan. The present disclosure, in view of the heart's characteristics that clearing away the heart fire and calming the nerves can ward off diseases and prolong life, and prevent premature aging, provides the prescription with the purpose of nourishing the blood and tranquillizing, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of nourishing the heart and tranquillizing.

Abstract: Carrageenan-based compositions containing a carrageenan, a starch, a plasticizer, water, and an optional buffer are disclosed, in which the carrageenan has both a potassium content of less than 4 wt. % and a viscosity configured to produce capsules on pressure-free rotary die equipment. Films and capsules can be formed from the carrageenan-based compositions.

Abstract: Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said glycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

Abstract: The present application discloses a nutritional composition for tonifying spleen. The nutritional composition includes the following components of raw materials in parts by weight: rice 50-90, soybean 8-23, Semen coicis 2-12, Gorgon euryale seed 3-12, poria 0.4-1.6, and Chinese date 0.3-1.5. The present disclosure, in view of the spleen's special susceptibility to dampness pathogen, complies with the physiological function characteristics of the spleen itself, provides the prescription with an assistant effect of restoring the spleen's function as a starting point, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of tonifying the spleen and removing dampness.

Abstract: The present application discloses a nutritional composition for moisturizing lung. The nutritional composition includes the following components of raw materials in parts by weight: rice 55-90, wheat 7-25, Chinese yam 3-15, lily 2-9, polygonatum odoratum 0.2-1, and citron 0.1-1. The present disclosure, in view of the lung's characteristics of being not resistant to cold or heat, and susceptible to pathogen, complies with the lung's physiological function characteristics to regulate, and provides the prescription with nourishing yin and moisturizing lung, and resolving phlegm and relieving cough as a starting point, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of replenishing and restoring lung qi.

Abstract: There is disclosed a composition for oral administration of O-desmethyltramadol. Compositions are also provided that are effective for overcoming resistance to tramadol in patients.

Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.

Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

Abstract: Provided herein is a ready-to-eat (RTE) breakfast cereal with a unique texture. A RTE breakfast cereal provided herein can have a high slowly digestible starch content relative to commercially available RTE cereals. Also disclosed are methods of making a RTE breakfast cereal described herein.

Abstract: An object is to provide an acid milk beverage, which shows no precipitation or aggregation and reduced whey separation, and which has a refreshing texture, even in cases where the acid milk beverage has a low solids-not-fat concentration. An acid milk beverage characterized by containing an acid milk beverage base and a pectin having an intrinsic viscosity of 5.9 to 8.5, a degree of esterification of 74 to 80, and a calcium reactivity of 230 or less is provided.

Abstract: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

Abstract: Disclosed are thickener compositions composed of xanthan gum and a chelating agent, such as ascorbic acid. The chelating agent is present in an amount with respect to said xanthan such that, when said thickener composition is used to thicken a food product, at least one mineral selected from the group consisting of iron, zinc, and calcium present in said food product is relatively more bioavailable than the mineral would be in the absence of said chelating agent. The thickener composition finds particular applicability for use with baby formulas and breast milk intended for dysphagic infants. Also disclosed are baby formulas and thickened breast milk formulations, methods for preparing same, and methods for providing nutrition.